{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:00Z","timestamp":1788316800625,"version":"build-2803163510"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This study was planned to compare the clinical results and optical coherence tomography (OCT) data of patients who underwent adalimumab (ADA), infliximab (IFX) and switched protocols between these two methods in cases of Beh\u00e7et\u2019s associated uveitis (BAU).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The patients with BAU who were treated with anti-TNF-\n                      <jats:italic toggle=\"yes\">\u03b1<\/jats:italic>\n                      agents for at least one year were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA), the central macular thickness (CMT), and the subfoveal choroidal thickness (SFCT) of the patients at the last visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      After a mean follow-up of 16.60 months, the rate of active inflammation decreased from 63.6% to 15.1%. Mean BCVA increased, mean CMT and mean SFCT decreased significantly at the last visit (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Anti-TNF-\n                      <jats:italic toggle=\"yes\">\u03b1<\/jats:italic>\n                      treatment and switching protocols between these two agents effectively and safely control intraocular inflammation in BAU patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2011_23","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:00:28Z","timestamp":1707181228000},"page":"S521-S528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Comparative results of use and switching of anti-TNF-alpha agents in adult Beh\u00e7et\u2019s uveitis"],"prefix":"10.4103","volume":"72","author":[{"given":"Selma","family":"Mesen","sequence":"first","affiliation":[{"name":"Turkoglu Dr. Kemal Beyazit State Hospital Eye Clinic, T\u00fcrko\u011flu, Kahramanmara\u015f, \u0130stanbul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet D","family":"Ozer","sequence":"additional","affiliation":[{"name":"Gaziosmanpa\u015fa Hospital Ophthalmology Department, Yeni Y\u00fczy\u0131l University, Zeytinburnu, \u0130stanbul"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Batur","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ophthalmology Department, Van Yuzuncu Yil University, Tu\u015fba, Van, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"R1-20260504","first-page":"1151","article-title":"Uber rezidivierende Aphthose, duruch ein Virus verursachte Geschwre am Mund am Auge und an den Genitalien","volume":"105","author":"Beh\u00e7et","year":"1937","journal-title":"Derm Wochr"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4274\/tjo.galenos.2019.60308","article-title":"Beh\u00e7et\u2019s uveitis: Current diagnostic and therapeutic approach","volume":"50","author":"\u00c7akar \u00d6zdal","year":"2020","journal-title":"Turk J Ophthalmol"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","article-title":"Epidemiology of Beh\u00e7et disease","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocular Immunol Inflamm"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3349\/ymj.2012.53.1.35","article-title":"New insights in the clinical understanding of Beh\u00e7et\u2019s disease","volume":"53","author":"Cho","year":"2012","journal-title":"Yonsei Med J"},{"key":"R5-20260504","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","article-title":"Prevalence of Beh\u00e7et\u2019s disease in Istanbul, Turkey","volume":"42","author":"Azizlerli","year":"2003","journal-title":"Int J Dermatol"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et\u2019s disease: New insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/112067210201200514","article-title":"Posterior segment involvement in ocular Beh\u00e7et\u2019s disease","volume":"12","author":"Ozdal","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"R8-20260504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: An analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R9-20260504","first-page":"301","article-title":"Efficacy of anti-tumour necrosis factor-\u03b1 monoclonal antibodies in patients with non-infectious anterior uveitis","volume":"37","author":"Fabiani","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R10-20260504","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Behcets\u2019 disease-associated uveitis: A systematic review and meta-analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front Pharmacol"},{"key":"R11-20260504","first-page":"621","article-title":"Efficacy of monoclonal anti-tumour necrosis factor-\u03b1 antibodies in uveitic macular oedema","volume":"38","author":"Tosi","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R12-20260504","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: A large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R13-20260504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20260504","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"R15-20260504","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"R16-20260504","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et\u2019s disease: A 1-year follow-up study of 124 patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology"},{"key":"R17-20260504","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/bjophthalmol-2014-305333","article-title":"Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Beh\u00e7et\u2019s disease","volume":"98","author":"Ishikawa","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R18-20260504","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease: A collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R19-20260504","first-page":"509","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"3","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R20-20260504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R21-20260504","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et\u2019s disease: A multicenter study","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"key":"R22-20260504","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: An open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R23-20260504","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","article-title":"Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease","volume":"18","author":"Bawazeer","year":"2010","journal-title":"Ocular Immunol Inflamm"},{"key":"R24-20260504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-year retention rate of infliximab in patients with Beh\u00e7et\u2019s disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocular Immunol Inflamm"},{"key":"R25-20260504","doi-asserted-by":"crossref","first-page":"107430","DOI":"10.1016\/j.intimp.2021.107430","article-title":"Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Beh\u00e7et\u2019s uveitis with vasculitis","volume":"93","author":"Yang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R26-20260504","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/bjophthalmol-2017-310733","article-title":"Cumulative retention rate of adalimumab in patients with Beh\u00e7et\u2019s disease-related uveitis: A four-year follow-up study","volume":"102","author":"Fabiani","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R27-20260504","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/annrheumdis-2019-eular.1606","article-title":"FRI0269 Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease. National multicenter study of 177 cases","volume":"78","author":"Atienza-Mateo","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R28-20260504","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2012-eular.2670","article-title":"FRI0213 Anti-TNF therapy in refractory uveitis of behcet\u2019s syndrome. A multicenter study of 63 patients","volume":"71","author":"Bejerano","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R29-20260504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower relapses rate with infliximab versus adalimumab in sight-threatening uveitis: A multicenter study of 330 patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R30-20260504","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye"},{"key":"R31-20260504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","volume":"31","author":"Takase","year":"2011","journal-title":"Rheumatol Int"},{"key":"R32-20260504","first-page":"301","article-title":"Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Beh\u00e7et\u2019s disease","volume":"9","author":"Karube","year":"2016","journal-title":"Int Med Case Rep J"},{"key":"R33-20260504","first-page":"54","article-title":"Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab","volume":"29","author":"Olivieri","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"R34-20260504","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1038\/s41598-019-45149-4","article-title":"Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Beh\u00e7et\u2019s uveitis","volume":"9","author":"Shirahama","year":"2019","journal-title":"Sci Rep"},{"key":"R35-20260504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1080\/09273948.2019.1611875","article-title":"Clinical and demographic features of pediatric-onset Beh\u00e7et\u2019s disease and evaluation of optical coherence tomography findings","volume":"28","author":"Balbaba","year":"2020","journal-title":"Ocular Immunol Inflamm"},{"key":"R36-20260504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.18502\/jovr.v16i2.9083","article-title":"Evaluation and comparison of choroidal thickness in patients with Beh\u00e7et disease with versus without ocular involvement","volume":"16","author":"Hosseini","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"key":"R37-20260504","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1167\/iovs.13-12231","article-title":"Choroidal thickness in Behcet\u2019s uveitis: An enhanced depth imaging-optical coherence tomography and its association with angiographic changes","volume":"54","author":"Kim","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-20260504","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/09273948.2016.1268169","article-title":"Long-term change of subfoveal choroidal thickness in Beh\u00e7et\u2019s disease patients with posterior uveitis","volume":"26","author":"Park","year":"2018","journal-title":"Ocular Immunol Inflamm"},{"key":"R39-20260504","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/bjophthalmol-2014-305333","article-title":"Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Beh\u00e7et\u2019s disease","volume":"98","author":"Ishikawa","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R40-20260504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"R41-20260504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0974-9233.58425","article-title":"Beh\u00e7et\u2019s uveitis","volume":"16","author":"Tugal-Tutkun","year":"2009","journal-title":"Middle East Afr J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2011_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:18:00Z","timestamp":1787768280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_2011_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":41,"journal-issue":{"issue":"Suppl 3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2011_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"assertion":[{"value":"2023-07-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}